acamprosate vs protriptyline
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of acamprosate and protriptyline. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Campral
Vivactil
Acamprosate is a medicine that can help you stay away from alcohol if you are alcohol-dependent and have already stopped drinking. It should be used with counseling and support.
Protriptyline (Vivactil) is a medicine used to treat depression. It can help improve mood and energy levels in adults under close medical supervision.
Acamprosate helps people who are alcohol-dependent to not drink alcohol. You must have already stopped drinking before you start taking acamprosate. This medicine works best when it is part of a complete treatment plan that includes counseling and support.
Protriptyline is used to treat symptoms of mental depression. It is especially helpful for people who are withdrawn and lack energy. Your doctor will monitor you closely while you are taking this medicine.
Acamprosate is similar to a natural substance in your brain. It is thought to work by helping to restore the normal balance of brain activity that is changed by long-term alcohol use. This can reduce your craving for alcohol.
Protriptyline is a tricyclic antidepressant. It works by affecting certain natural chemicals in the brain. These chemicals help regulate mood.
- • Accidental injury
- • Weakness
- • Pain
- • Loss of appetite
- • Diarrhea
No common side effects listed.
- Hypotension 14
- Asthenia 13
- Condition Aggravated 13
- Acute Kidney Injury 12
- Coma 12
- Fall 12
- Product Administration Interrupted 8
- Sleep Apnoea Syndrome 8
- Anxiety 7
- Depression 6
Acamprosate may increase the risk of suicidal thoughts or actions. Your doctor should watch you for depression or suicidal thoughts. Tell your doctor right away if you have any new or worsening symptoms of depression or suicidal thoughts.
Antidepressants may increase the risk of suicidal thoughts and behaviors in children, teenagers, and young adults. Your doctor will closely monitor you for worsening depression, suicidal thoughts, or unusual changes in behavior. Families and caregivers should also watch for these changes. Protriptyline is not approved for use in children.
Acamprosate may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if acamprosate passes into breast milk. Talk to your doctor if you are breastfeeding.
Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. It is not known if protriptyline will harm an unborn baby. Talk to your doctor about the risks and benefits of taking this medicine during pregnancy or while breastfeeding.
Also Compare, Nearby Drugs
Compare protriptyline with
How to Read This acamprosate vs protriptyline Comparison
acamprosate is classified in the GABA Analog (Alcohol Dependence) drug class, while protriptyline sits within the Tricyclic Antidepressant (TCA) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, acamprosate has 64 submissions while protriptyline has 41. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for acamprosate or protriptyline.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.